Zepp Health Corporation (ZEPP) Q2 2025 Earnings Call Transcript

Zepp Health Corporation reported a significant turnaround in Q2 2025, achieving its first year-over-year revenue growth since Q2 2021, with sales surging 46% to $59.4 million. The company narrowed its adjusted operating loss to $4.9 million and issued strong Q3 revenue guidance of $72-76 million, representing 70-79% YoY growth. This performance was fueled by robust demand for its Amazfit-branded products, including the T-Rex, Balance 2, and newly launched Helio Strap, strategic AI integration in Zepp OS 5.0, and effective supply chain diversification, collectively signaling a positive trajectory in its business transformation and a potential revaluation by the market.

Analysis

Zepp Health Corporation (ZEPP) reported a significant operational and financial turnaround in its Q2 2025 results, marking a pivotal moment in its business transformation. Revenue surged 46% year-over-year to $59.4 million, representing the first YoY growth since Q2 2021 and exceeding the upper end of guidance. This growth was driven by a comprehensive product strategy, with strong demand for both entry-level models like the Bip 6 and Active 2, and sustained momentum in the premium T-Rex series. The company's strategic pivot towards premiumization is further evidenced by the launch of the Balance 2 smartwatch and the Helio Strap, a subscription-free tracker praised for best-in-class heart rate accuracy, which is currently facing supply constraints due to high demand. While gross margin was 36.2%, slightly down YoY due to product mix and promotional clearances, management projects margin expansion in the second half, supported by a full quarter of sales from these new higher-margin products. Operationally, the company has effectively mitigated geopolitical tariff risks by leveraging its diversified manufacturing footprint in China and Vietnam. This operational resilience, coupled with disciplined cost controls that narrowed the adjusted operating loss by 42% to $4.9 million and a robust Q3 revenue forecast of $72-76 million (70-79% YoY growth), signals strong execution and reinforces management's confidence in a sustained growth trajectory.

Key Decisions for Investors

• Investors should consider the exceptionally strong Q3 revenue guidance of 70-79% YoY growth as a primary indicator that the company's turnaround is gaining significant momentum, potentially supporting the value re-evaluation mentioned by management.
• Monitor gross margin performance in the upcoming quarters to verify that the new premium products, Balance 2 and Helio Strap, are successfully shifting the product mix and driving margins toward the company's medium-term goal of over 40%.
• Assess the company's ability to resolve supply constraints for the popular new Helio Strap in Q3, as meeting demand for this competitively differentiated product is crucial for capitalizing on its market traction and driving future growth.
• Given the reaffirmed share repurchase program and management's commentary on undervaluation, it may be prudent to re-evaluate ZEPP's valuation relative to peers in light of its renewed growth profile and improved operational fundamentals.